Eloise Mastrangelo


Actual position. Since June 2005, CNR research staff. My first tasks are the protein expression and purification (in E.Coli and Baculo), the treatment and the chemical-physical characterization of recombinant proteins, the 3D protein structure solution, structural-based drug design and optimization.
2007-2009: PhD in Molecular and Cellular Biology at the Department of Biomolecular Sciences and Biotechnology, University of Milano
2003-2005: scientist at Sienabiotech S.p.A.
2001-2003: fellowship within the “National Program of Oncology Research
2000-2001: Yearly collaboration with “Società Prodotti Antibiotici” in Florence
1999-2000: Experimental thesis in Chemistry at the University of Florence. Final mark: 110 cum laude/110



- Email eloise.mastrangelo@unimi.it
- Phone +39-02-50314890
- Site Milano



Research interests:

- Structure-based drug discovery (Principal investigator)

- Structural and biochemical bases of the pathogenicity of the Apoptosis Inducing Factor (AIF)

- Structure-based drug discovery on viral proteins

- Gelsolin physiopathology

- Structural analysis of proteins involved in various human diseases and research of new therapeutic strategies

Further collaborations:

- Pierfausto Seneci (Università degli studi di Milano)
- Alessandro Aliverti (Università degli studi di Milano)
- Alessandro Marcello (ICGEB, Trieste)
- Oscar Burrone (ICGEB, Trieste)
- Francesca Arnoldi (ICGEB, Trieste)
- Violetta Cecchetti (Università degli studi di Perugia)
- Giuseppe Manfroni (Università degli studi di Perugia)
- Daniele Lecis (Istituto Tumori Milano)
- Daniele dell’Orco (Università degli studi di Verona)
- Leonardo Manzoni (Cnr-Istm)
- Jilles Querat (Université de la Méditerranée, Marseille, France)
- Johan Neyts (Katholieke Universiteit Leuven, Belgium)

Key publications:

Cannalire R, Tarantino D, Astolfi A, Barreca ML, Sabatini S, Massari S, Tabarrini O, Milani M, Querat G, Mastrangelo E*, Manfroni G, Cecchetti V (2017) Functionalized 2,1-benzothiazine 2,2-dioxides as new inhibitors of Dengue NS5 RNA-dependent RNA polymerase. Eur J Med Chem. 143:1667-1676. doi: 10.1016/j.ejmech.2017.10.064. *co-corresponding author

Mastrangelo E, Vachette P, Cossu F, Malvezzi F, Bolognesi M, Milani M (2015) The activator of apoptosis Smac-DIABLO acts as a tetramer in solution. Biophys J. 108(3):714-23. doi: 10.1016/j.bpj.2014.11.3471

Cossu F, Milani M, Vachette P, Malvezzi F, Grassi S, Lecis D, Delia D, Drago C, Seneci P, Bolognesi M, Mastrangelo E* (2012) Structural insight into inhibitor of apoptosis proteins recognition by a potent divalent smac-mimetic. PLoS One 7(11):e49527 *corresponding author

Mastrangelo E, Pezzullo M, De Burghgraeve T, Kaptein S, Pastorino B, Dallmeier K, de Lamballerie X, Neyts J, Hanson AM, Frick DN, Bolognesi M, Milani M (2012) Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. J Antimicrob Chemother 67(8):1884-94

Lecis D*, Mastrangelo E*, Belvisi L, Bolognesi M, Civera M, Cossu F, De Cesare M, Delia D, Drago C, Manenti G, Manzoni L, Milani M, Moroni E, Perego P, Potenza D, Rizzo V, Scavullo C, Scolastico C, Servida F, Vasile F, Seneci P (2012) Dimeric Smac mimetics/IAP inhibitors as in vivo-active pro-apoptotic agents. Part II: Structural and biological characterization. Bioorg Med Chem. 20(22):6709-23. doi: 10.1016/j.bmc.2012.09.041. *Equal contribution

Publication list